Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
IJSREM66548
Volume:
10 |
8 |
Aug 2026
Pages:
1-7
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
FOODS AND NUTRITION
PSG COLLGE OF ARTS AND SCIENCE
FOODS AND NUTRITION
PSG COLLGE OF ARTS AND SCIENCE
Background: Glucolipid metabolic disorders—encompassing central obesity, non-alcoholic fatty liver disease (NAFLD), insulin resistance, and dyslipidemia—present a critical global health burden driven predominantly by energy-dense, high-sugar high-fat diets (HSFD). Conventional therapeutic agents are frequently accompanied by long-term adverse events, prompting interest in natural dietary interventions. This study investigated the proive efficacy and molecular mechanisms of aqueous Coriandrum sativum seed extract (YS) in an HSFD-induced mouse model. Methods: Phytochemical profiling of YS was conducted via gas chromatography-mass spectrometry (GC-MS). Male Kunming mice received an HSFD along with oral gavage of YS at 1.0 g/kg/day (YS-L) or 2.0 g/kg/day (YS-H) for eight consecutive weeks. Physiological parameters, glucose/insulin dynamics (HOMA-IR), serum and hepatic lipid profiles (TC, TG, LDL-C), liver enzymes (ALT, AST, AKP), and redox status (SOD, MDA) were quantified. Histopathological changes in hepatic, pancreatic, and colonic tissues were evaluated alongside hepatic gene and protein expression (FAS, NF-κB, IL-6, PPARα, LDLR). Gut microbiota dynamics were profiled using full-length 16S rRNA gene sequencing paired with PICRUSt2 functional predictions. Results: GC-MS identified nine major constituents in YS, led by 4-ethenyl-2-methoxyphenol (11.62%) and hexadecanoic acid (6.13%). YS treatment dose-dependently mitigated body weight gain, visceral adiposity, hyperglycemia, hyperinsulinemia, and HOMA-IR while rescuing hepatic glycogen storage. YS normalized lipid profiles, lowered ALT, AST, and AKP levels, reduced MDA, and elevated SOD activity. Histopathology confirmed structural proion across hepatic, pancreatic, and colonic tissues. At the molecular level, YS suppressed hepatic expression of lipogenic (FAS) and pro-inflammatory (NF-κB, IL-6) targets while upregulating PPARα and LDLR protein expression. Full-length 16S rRNA sequencing showed that YS restored microbial diversity, enriching beneficial taxa (Lactobacillus murinus, Lachnospiraceae_UCG-006, Streptococcus danieliae) and suppressing pro-inflammatory Desulfovibrio, alongside enriching carbohydrate and energy metabolic pathways. Conclusion: Aqueous Coriandrum sativum seed extract serves as a potent, multi-targeted natural agent capable of reversing diet-induced glucolipid metabolic disorders through coordinated regulation of lipid metabolism, inflammation, and gut microbial ecosystem dynamics along the gut-liver axis.
KEYWORDS
This study demonstrates that aqueous Coriandrum sativum seed extract effectively ameliorates high-fat, high-sugar diet-induced glucolipid metabolic disorders in mice. Through multi-target actions along the gut-liver axis, YS intervention: Improves glycemic control, lowers systemic insulin resistance, and preserves pancreatic islet archiure. Reduces serum and hepatic lipid accumulation while proing against liver injury and oxidative stress. Modulates key hepatic targets by suppressing lipogenic (FAS) and inflammatory (NF-κB, IL-6) pathways while promoting lipid oxidation and clearance (PPARα, LDLR). Restores intestinal mucosal integrity and reshapes the gut microbiota by enriching beneficial taxa (Lactobacillus murinus, Lachnospiraceae_UCG-006) and suppressing pro-inflammatory microbes (Desulfovibrio).Overall, these findings support the potential of Coriandrum sativum seed extract as a functional food component or natural therapeutic agent for the management of metabolic syndrome, NAFLD, and type 2 diabetes.
1. Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., Waget, A., Delmée, E., Cousin, B., Sulpice, T., Chamontin, B., Ferrières, J., Tanti, J.-F., Gibson, G. R., Casteilla, L., . . . Burcelin, R. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56(7), 1761–1772. https://doi.org/10.2337/db06-1491 2. Fan, J.-G., Kim, S. U., & Wong, V. W.-S. (2017). New trends on obesity and NAFLD in Asia. Journal of Hepatology, 67(4), 862–873. https://doi.org/10.1016/j.jhep.2017.06.011 3. Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137–188. https://doi.org/10.1152/physrev.00045.2011 4. Go, G. (2012). Low-Density Lipoprotein Receptor (LDLR) Family Orchestrates Cholesterol Homeostasis. Journal of Lipids. Cited by: 571 5. Gu, M. J., Ahn, Y., Lee, Y. R., Yoo, G., Kim, Y., Choi, I., Ha, S. K., & Kim, D. (2024). Coriandrum sativum L. Leaf Extract Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating the AMPK Pathway in High Fat-Fed C57BL/6 Mice. Nutrients, 16(23), 4165. https://doi.org/10.3390/nu16234165 Cited by: 6 6. Gu, M. J., Ahn, Y., Lee, Y. R., Yoo, G., Kim, Y., Choi, I., Ha, S. K., & Kim, D. (2024). Coriandrum sativum L. Leaf Extract Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating the AMPK Pathway in High Fat-Fed C57BL/6 Mice. Nutrients, 16(23), 4165. https://doi.org/10.3390/nu16234165 Cited by: 6 7. Hong, Y., Sheng, L., Zhong, J., Tao, X., Zhu, W., Ma, J., Yan, J., Zhao, A., Zheng, X., Wu, G., Li, B., Han, B., Ding, K., Zheng, N., Jia, W., & Li, H. (2021). Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. Gut Microbes, 13(1), 1–19. https://doi.org/10.1080/19490976.2021.1930874 Cited by: 293 8. Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015). Gut–liver axis, nutrition, and non-alcoholic fatty liver disease. Clinical Biochemistry, 48(14–15), 923–930. https://doi.org/10.1016/j.clinbiochem.2015.06.023 Cited by: 437 9. Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015). Gut–liver axis, nutrition, and non-alcoholic fatty liver disease. Clinical Biochemistry, 48(14–15), 923–930. https://doi.org/10.1016/j.clinbiochem.2015.06.023 Cited by: 437 10. Lee, N. Y., Shin, M. J., Youn, G. S., Yoon, S. J., Choi, Y. R., Kim, H. S., Gupta, H., Han, S. H., Kim, B. K., Lee, D. Y., Park, T. S., Sung, H., Kim, B. Y., & Suk, K. T. (2021). Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clinical and Molecular Hepatology, 27(1), 110–124. https://doi.org/10.3350/cmh.2020.0125 Cited by: 150
Publication Date
8/6/2026
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
3
Total views since publication
PDF Downloads
8
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...